Under-the-Radar Biotechs to Watch: Axsome Therapeutics and Exelixis

Axsome Therapeutics (AXSM) and Exelixis (EXEL) are under-the-radar biotech stocks with strong prospects. Axsome Therapeutics has a growing revenue base and multiple new products in development, including Auvelity for major depressive disorder and Symbravo for migraines. Exelixis specializes in cancer medicine and has been successful with its Cabometyx therapy. Both companies have a high potential for growth and could be attractive buys heading into 2026.